As shown in an earlier study by our group, the prototype proteasome inhibitor bortezomib has a dual mechanism of action in GIST through upregulation of the pro-apoptotic histone H2AX and inhibition of transcription resulting in loss of KIT expression6. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.